Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC trimmed its holdings in Health Catalyst, Inc. (NASDAQ:HCAT) by 55.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 49,496 shares of the company’s stock after selling 60,744 shares during the period. Janney Montgomery Scott LLC owned 0.08% of Health Catalyst worth $350,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Impax Asset Management Group plc lifted its stake in shares of Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after purchasing an additional 360,201 shares in the last quarter. Primecap Management Co. CA raised its holdings in Health Catalyst by 1.1% during the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after buying an additional 25,000 shares during the period. Nepsis Inc. grew its holdings in shares of Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after buying an additional 851,448 shares in the last quarter. Geode Capital Management LLC boosted its position in Health Catalyst by 4.9% during the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after purchasing an additional 66,896 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Health Catalyst by 2.5% during the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after buying an additional 28,251 shares during the period. Institutional investors and hedge funds own 85.00% of the company’s stock.

Insider Transactions at Health Catalyst

In other news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the transaction, the insider now owns 236,950 shares in the company, valued at approximately $2,118,333. This trade represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $7.88, for a total transaction of $50,762.96. Following the completion of the sale, the insider now owns 98,702 shares of the company’s stock, valued at $777,771.76. This trade represents a 6.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 81,169 shares of company stock worth $629,068. 2.50% of the stock is currently owned by corporate insiders.

Health Catalyst Trading Up 0.9 %

Shares of HCAT stock opened at $5.75 on Tuesday. The company has a market capitalization of $349.89 million, a PE ratio of -4.26 and a beta of 1.34. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The business’s fifty day moving average is $6.80 and its 200 day moving average is $7.41. Health Catalyst, Inc. has a 52-week low of $5.32 and a 52-week high of $10.31.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on HCAT shares. Stephens raised their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Wells Fargo & Company lowered their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Piper Sandler restated an “overweight” rating and set a $12.00 price objective (up from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Royal Bank of Canada decreased their price target on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 15th. Finally, KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a research report on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.60.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.